From radiobiology to technology: what is changing in radiotherapy for prostate cancer

References

• NCCN. Available from: www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
   Google Scholar
• Heidenreich A, Bellmunt J, Bolla M, et al. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59(1):61-71
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59(4):572-83
   PubMed Web of Science ®Google Scholar
• Bauman G, Rumble RB, Chen J, et al. Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin Oncol 2012;24(7):461-73
   Web of Science ®Google Scholar
• Zelefsky MJ, Fuks Z, Happersett L, et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000;55:241-9
   PubMed Web of Science ®Google Scholar
• Staffurth J. Radiotherapy Development Board. A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol 2010;22(8):643-57
   Web of Science ®Google Scholar
• Mitchell JM. Urologists' use of intensity-modulated radiation therapy for prostate cancer. N Engl J Med 2013;369(17):1629-37
   PubMedGoogle Scholar
• Fogarty GB, Ng D, Liu G, et al. Volumetric modulated arc therapy is superior to conventional intensity modulated radiotherapy - a comparison among prostate cancer patients treated in an Australian centre. Radiat Oncol 2011;6(1):108
   PubMedGoogle Scholar
• Rong Y, Tang G, Welsh JS, et al. Helical tomotherapy versus single-arc intensity-modulated arc therapy: a collaborative dosimetric comparison between two institutions. Int J Radiat Oncol Biol Phys 2011;81(1):284-96
   PubMedGoogle Scholar
• Davidson MT, Blake SJ, Batchelar DL, et al. Assessing the role of volumetric modulated arc therapy (VMAT) relative to IMRT and helical tomotherapy in the management of localized, locally advanced, and post-operative prostate cancer. Int J Radiat Oncol Biol Phys 2011;80(5):1550-8
   PubMedGoogle Scholar
• Davidson MT, Blake SJ, Batchelar DL, et al. Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review. Radiother Oncol 2009;93(2):168-73
   PubMedGoogle Scholar
• Udrescu C, De Bari B, Rouvière O, et al. Does hormone therapy modify the position of the gold markers in the prostate during irradiation? A daily evaluation with kV-images. Cancer Radiother 2013;17(3):215-20
   PubMedGoogle Scholar
• Udrescu C, Jalade P, de Bari B, et al. Evaluation of the respiratory prostate motion with four-dimensional computed tomography scan acquisitions using three implanted markers. Radiother Oncol 2012;103(2):266-9
   PubMedGoogle Scholar
• Magrini SM, Bertoni F, Vavassori V, et al. Practice patterns for prostate cancer in nine central and northern Italy radiation oncology centers: a survey including. 1759 patients treated during two decades (1980-1998. Int J Radiat Oncol Biol Phys 2002;52(5):1310-19
   PubMedGoogle Scholar
• Pegurri L, Buglione M, Girelli G, et al. Changes in patterns of practice for prostate cancer radiotherapy in Italy. 1995-2003. A survey of the Prostate Cancer Study Group of the Italian Radiation Oncology Society (AIRO). Tumori 2013; In press
   Google Scholar
• Steel GG. Basic clinical radiobiology. Arnold; London, UK: 2003
   Google Scholar
• Brenner DJ, Martinez AA, Edmundson GK, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002;52(1):6-13
   PubMed Web of Science ®Google Scholar
• Fowler J, Chappel R, Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001;50:1021-31
   PubMed Web of Science ®Google Scholar
• Arcangeli S, Scorsetti M, Along F. Will. SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review. Crit Rev Oncol Hematol 2012;84:101-8
   PubMed Web of Science ®Google Scholar
• Williams SG, Taylor JM, Liu N, et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 2007;68:24-33
   PubMed Web of Science ®Google Scholar
• Dasu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol 2007;19(5):289-301
   Web of Science ®Google Scholar
• Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 2012;82(1):e17-24
   PubMedGoogle Scholar
• Proust-Lima C, Taylor JM, Sécher S, et al. Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys 2011;79(1):195-201
   PubMed Web of Science ®Google Scholar
• Pedicini P, Caivano R, Strigari L, et al. In regard to Miralbell et al. Int J Radiat Oncol Biol Phys 2013;85(1):10-11
   PubMedGoogle Scholar
• Pedicini P. In regard to pedicini et al. Int J Radiat Oncol Biol Phys 2013;87(5):858
   PubMedGoogle Scholar
• Pollack AW, Walker G, Horwitz EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 2013;31(31):3860-8
   PubMed Web of Science ®Google Scholar
• Alongi F, Di Muzio N. Image-guided radiation therapy: a new era for the radiation oncologist? Int J Clin Oncol 2009;14(6):568-9
   PubMedGoogle Scholar
• Zaorsky NG, Harrison AS, Trabulsi EJ, et al. Evolution of advanced technologies in prostate cancer radiotherapy. Nat Rev Urol 2013;10(10):565-79
   PubMed Web of Science ®Google Scholar
• Hartford AC, Galvin JM, Beyer DC, et al. American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for Intensity-modulated Radiation Therapy (IMRT). Am J Clin Oncol 2012;35(6):612-17
   PubMedGoogle Scholar
• Bauman G, Rumble RB, Chen J, et al. Members of the IMRT Indications Expert Panel. Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin Oncol 2012;24(7):461-73
   Web of Science ®Google Scholar
• Zelefsky MJ, Kollmeier M, Cox B, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2012;84:125-9
   PubMed Web of Science ®Google Scholar
• Munoz F, Fiandra C, Franco P, et al. Tracking target position variability using intraprostatic fiducial markers and electronic portal imaging in prostate cancer radiotherapy. Radiol Med 2012;117:1057-70
   PubMed Web of Science ®Google Scholar
• Udrescu C, De Bari B, Rouvière O, et al. Does hormone therapy modify the position of the gold markers in the prostate during irradiation? A daily evaluation with kV-images. Cancer Radiother 2013;17(3):215-20
   PubMedGoogle Scholar
• Zaorsky NG, Studenski MT, Dicker AP, et al. Stereotactic body radiation therapy for prostate cancer: is technology ready to be the standard of care? Cancer Treat Rev 2013;39:212-18
   PubMed Web of Science ®Google Scholar
• De Bari B, Fiorentino A, Greto D, et al. Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the Italian young radiation oncologist meeting. Tumori 2013;99:637-49
   PubMed Web of Science ®Google Scholar
• Alongi F, De Bari B, Franco P, et al. The PROCAINA (PROstate CAncer INdication Attitudes) Project (Part I): a survey among Italian radiation oncologists on postoperative radiotherapy in prostate cancer. Radiol Med 2013;118(4):660-78
   PubMed Web of Science ®Google Scholar
• De Bari B, Alongi F, Franco P, et al. The “PROCAINA (PROstate CAncer INdication Attitudes) Project” (Part II) - A survey among Italian radiation oncologists on radical radiotherapy in prostate cancer. Radiol Med 2013;118(7):1220-39
   PubMed Web of Science ®Google Scholar
• Lukka H, Hayter C, Julian JA, et al. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005;23:6132-8
   PubMed Web of Science ®Google Scholar
• Yeoh EE, Botten RJ, Butters J, et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of Phase III randomized trial. Int J Radiat Oncol Biol Phys 2011;81:1271-8
   PubMed Web of Science ®Google Scholar
• Kuban DA, Nogueras-Gonzalez NG, Hamblin L, et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. Int J Radiat Oncol Biol Phys 2010;78(Suppl):S58
   PubMedGoogle Scholar
• Arcangeli G, Saracino B, Gomellini S, et al. A prospective Phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010;78(1):11-18
   PubMed Web of Science ®Google Scholar
• Arcangeli S, Strigari L, Gomellini S, et al. Updated results and pattern of failures in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012;84:1172-8
   PubMed Web of Science ®Google Scholar
• Higgins GS, McLaren DB, Kerr GR, et al. Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys 2006;65:982-9
   PubMedGoogle Scholar
• Kuban D, Tucker S, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70(1):67-74
   PubMed Web of Science ®Google Scholar
• Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from MRC RT01 randomised controlled trial. Lancet Oncol 2007;8:475-87
   PubMed Web of Science ®Google Scholar
• Al-Magmani AA, Heemsbergen WD, Levendag PC, Lebesque JV. Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose-escalation trial. Radiother Oncol 2012;96:13-18
   Google Scholar
• Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastasis-free survival. Int J Radiat Oncol Biol Phys 2008;71:1028-33
   PubMed Web of Science ®Google Scholar
• Kuban D, Pollack A, Huang E, et al. Hazard of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:1260-8
   PubMed Web of Science ®Google Scholar
• Dearnaley D, Syndicus I, Sumo G, et al. Conventional versus hypofractionated high dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from CHHiP randomized controlled trial. Lancet Oncol 2012;13:4354
   Google Scholar
• Katz AJ, Santoro M, Ashley R, et al. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 2010;10:1
   PubMed Web of Science ®Google Scholar
• Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 2011;6:3
   PubMed Web of Science ®Google Scholar
• McBride SM, Wong DS, Dombrowski JJ, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional Phase 1 feasibility trial. Cancer 2011;118(15):3681-90
   PubMedGoogle Scholar
• Fuller DB, Shirazi R, Naitoh J, et al. Virtual HDR SBRT. For localized prostatic carcinoma: efficacy and quality of life assessment. Int J Radiat Oncol Biol Phys 2011;81:S423-4
   Google Scholar
• Kang JK, Cho CK, Choi CW, et al. Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori 2011;97:43-8
   PubMed Web of Science ®Google Scholar
• King CR, Brooks JD, Gill H, Presti JC Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012;82(2):877-82
   PubMed Web of Science ®Google Scholar
• Madsen BL, Hsi RA, Pham HT, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007;67:1099-105
   PubMed Web of Science ®Google Scholar
• Boike TP, Lotan Y, Cho LC, et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 2011;29:2020-6
   PubMed Web of Science ®Google Scholar
• Loblaw A, Cheung P, D'Alimonte L, et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother Oncol 2013;107(2):153-8
   PubMed Web of Science ®Google Scholar
• Lukka HR. A Randomized Phase II trial of hypofractionated radiotherapy for favorable risk prostate cancer-RTOG CCOP Study; 201125. Katz AJ Personal communication American Society Therapeutic Radiation Oncology annual meeting; 2012
   Google Scholar
• Zamboglou N, Tselis N, Baltas D, et al. High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. Int J Radiat Oncol Biol Phys 2013;85:672-8
   PubMedGoogle Scholar
• Tselis N, Tunn UW, Chatzikonstantinou G, et al. High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients. Radiat Oncol 2013;8:115
   PubMedGoogle Scholar
• Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:2035-41
   PubMed Web of Science ®Google Scholar
• Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005;366:572-8
   PubMed Web of Science ®Google Scholar
• Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006;296:2329-35
   PubMed Web of Science ®Google Scholar
• Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009;27:2924-30
   PubMed Web of Science ®Google Scholar
• Kruser TJ, Jarrard DF, Graf AK, et al. Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence. Cancer 2011;117:2629-36
   PubMed Web of Science ®Google Scholar
• Cozzarini C, Fiorino C, Di Muzio N, et al. Hypofractionated adjuvant radiotherapy with helical tomotherapy after radical prostatectomy: planning data and toxicity results of a Phase I-II study. Radiother Oncol 2008;88:26-33
   PubMedGoogle Scholar
• Massaccesi M, Cilla S, Deodato F, et al. Hypofractionated intensity-modulated radiotherapy with simultaneous integrated boost after radical prostatectomy: preliminary results of a Phase II trial. Anticancer Res 2013;33(6):2785-9
   PubMedGoogle Scholar
• Alongi F, De Bari B, Campostrini F, et al. Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: a review. Crit Rev Oncol Hematol 2013;88(3):550-63
   PubMed Web of Science ®Google Scholar
• Wallner KE, Nori D, Morse MJ, et al. 125iodine reimplantation for locally progressive prostatic carcinoma. J Urol 1990;144:704-6
   PubMedGoogle Scholar
• Loening SA, Turner JW. Use of percutaneous transperineal 198Au seeds to treat recurrent prostate adenocarcinoma after failure of definitive radiotherapy. Prostate 1993;23:283-90
   PubMedGoogle Scholar
• Nguyen PL, Chen MH, D'Amico AV, et al. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective Phase 2 study. Cancer 2007;110(7):1485-92
   PubMed Web of Science ®Google Scholar
• Koutrouvelis P, Hendricks F, Lailas N, et al. Salvage reimplantation in patient with local recurrent prostate carcinoma after brachytherapy with three dimensional computed tomography-guided permanent pararectal implant. Technol Cancer Res Treat 2003;2:339-44
   PubMedGoogle Scholar
• Beyer DC. Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology 1999;54(5):880-3
   PubMedGoogle Scholar
• Wong WW, Buskirk SJ, Schild SE, et al. Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation. J Urol 2006;176(5):2020-4
   PubMedGoogle Scholar
• Moman MR, van der Poel HG, Battermann JJ, et al. Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrences after primary 125-I implantation and external beam radiotherapy. Brachytherapy 2010;9(2):119-25
   PubMed Web of Science ®Google Scholar
• Burri RJ, Stone NN, Unger P, Stock RG. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010;77(5):1338-44
   PubMed Web of Science ®Google Scholar
• Grado GL, Collins JM, Kriegshauser JS, et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999;53:2-10
   PubMedGoogle Scholar
• Hsu CC, Hsu H, Pickett B, et al. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial ppi for prostate cancer. Int J Radiat Oncol Biol Phys 2013;85(2):370-7
   PubMedGoogle Scholar
• Jo Y, Fujii T, Hara R, et al. Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radiotherapy - preliminary results. BJU Int 2012;109(6):835-9
   PubMedGoogle Scholar
• Lee B, Shinohara K, Weinberg V, et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 2007;67:1106-12
   PubMedGoogle Scholar
• Chen CP, Weinberg V, Shinohara K, et al. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys 2013;86(2):324-9
   PubMed Web of Science ®Google Scholar
• Ramey SJ, Marshall DT. Re-irradiation for salvage of prostate cancer failures after primary radiotherapy. World J Urol 2013;31(6):1339-45
   PubMedGoogle Scholar
• Kalapurakal JA, Mittal BB, Sathiaseelan V. Re-irradiation and external hypertheramia in locally advanced, radiation recurrent, hormone refractory prostate cancer: a preliminary report. Br J Radiol 2001;74:745-51
   PubMed Web of Science ®Google Scholar
• Ricchetti F, Barra S, Agostinelli S, et al. Feasibility of helical tomotherapy for radical dose retreatment in pelvic area: a report of 4 cases. Tumori 2011;97:492-7
   PubMedGoogle Scholar
• Jereczek-Fossa BA, Orecchia R. Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radiother Oncol 2007;84:197-215
   PubMed Web of Science ®Google Scholar
• Vavassori A, Jereczek-Fossa BA, Beltramo G, et al. Image-guided robotic radiosurgery as salvage therapy for locally recurrent prostate cancer after external beam irradiation: retrospective feasibility study on six cases. Tumori 2010;96:71-5
   PubMed Web of Science ®Google Scholar
• Jereczek-Fossa BA, Beltramo G, Fariselli L, et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastastic prostate cancer. Int J Radiat Oncol Biol Phys 2012;82:889-97
   PubMed Web of Science ®Google Scholar